KIT and gastrointestinal stromal tumor: The response of GIST to imatinib varies with the primary KIT mutation genotype; patients with C-KIT exon 9 or 13 mutations have shorter median recurrence times on imatinib compared to those with C-KIT exon 11 mutations (34).